Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study

Clinical Infectious Diseases

Volumn 32, Issue 3, 2001, Pages 402-412

  Rubinstein, E ^a   Cammarata, S K ^a   Oliphant, T H ^a   Wunderink, R G ^a   Labrooy, J ^a   Moran, J L ^a   Richards, B ^a   Grimard, D ^a   Landis, S J ^a   Rotstein, C ^a   Chavez, E ^a   Northland, R ^a   Triantafilo, V ^a   Vasquez, P ^a   Kolek, V ^a   Kucera, M ^a   Reiterer, P ^a   Weidenhoffer, I ^a   Andrews, C ^a   McLaren, I ^a   Street, M ^a   Ali Malkkila T ^a   Heikkinen, J ^a   Kairi, P ^a   Valtonen, M ^a   Georges, B ^a   Holzapfel, L ^a   Leon, A ^a   Martin, C D ^a   Maurette, P ^a   Muir, J F ^a   Ossart, M ^a   Veber, B ^a   Lukacs, J ^a   Nagy, G ^a   Rott, Z ^a   Raz, R ^a   Riesenberg, K ^a   Yinnon, A ^a   Molinari, M ^a   Castro, G ^a   Fabian, G ^a   Gaca, M ^a   Krawczyk, L ^a   Malolepszy, J ^a   Szulc, R ^a   Wolowicka, L ^a   Chuchalin, A G ^a   Fedorova, T ^a   Kakhnovskii, I M ^a   Novozhenov, V G ^a   Sinopalnikov, A I ^a   Kilian, J G ^a   Michell, W L ^a   Sturm, A W ^a   Viljoen, J ^a   Wood, R ^a   Pueyo, J M ^a   Soler Obradors, M ^a   Baird, I M ^a   Birmingham, M C ^a   Bjerke, H S ^a   Brown, M A ^a   Chow, S J D ^a   Daniels, R K ^a   Dickey, T ^a   El Solh, A ^a   Graham, D R ^a   Grier, L R ^a   Hall, J ^a   Harrison, M S ^a   Herbert, M T ^a   Hyzy, R C ^a   Kaner, R J ^a   Larsen, L S ^a   Leviton, I ^a   Matchett, S C ^a   Metzler, M H ^a   Morganroth, M L ^a   Murthy, A R ^a   Nolan, P E ^a   Olson, N H ^a   Palmer, L B ^a   Postier, R G ^a   Remy, D P ^a   Richmond, G J ^a   Rosenthal, M H ^a   Sanchez, G ^a   Schechter, R B ^a   Simon, S J ^a   Smith, T W ^a   Thompson, B ^a   White, B J ^a   Hafkin, B ^a   Todd, W M ^a   Timm, J ^a   Hempsall, K ^a   Schuemann, L ^a   more..

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; LINEZOLID; VANCOMYCIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTICENTER STUDY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; THORAX RADIOGRAPHY;

ACETAMIDES; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZTREONAM; CROSS INFECTION; DOUBLE-BLIND METHOD; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; GRAM-POSITIVE BACTERIA; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MONOBACTAMS; OXAZOLIDINONES; PNEUMONIA; SAFETY; TIME FACTORS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 0035112879     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/318486     Document Type: Article

References (58)

1. The diagnosis and treatment challenges in nosocomial pneumonia
2. Opportunistic nosocomial multiply resistant bacterial infections: Their treatment and prevention
3. Hospital-acquired pneumonia
4. Epidemiology of nosocomial pneumonia in intensive care unit patients
5. Nosocomial pneumonia on general medical and surgical wards in a tertiary-care hospital
6. Risk factors for ICU-acquired pneumonia
7. Preventing nosocomial pneumonia: State of the art and perspectives for the 1990s
8. Guideline for the prevention of nosocomial pneumonia. Part I. Issues on prevention of nosocomial pneumonia, 1994
9. Nosocomial infection surveillance, 1984
10. Epidemiology of nosocomial pneumonia: New perspectives on an old disease
11. Nosocomial pneumonia in Medicare patients: Hospital costs and reimbursement patterns under the prospective payment system
12. Effect of intensive care unit nosocomial pneumonia on duration of stay and mortality
13. Nosocomial infections in medical intensive care units in the United States
14. Bird's-eye view of nosocomial infections in medical ICU: Blue bugs, fungi, and device days
15. The influence of mini-BAL cultures on patient outcomes: Implications for the antibiotic management of ventilator-associated pneumonia
16. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia
17. Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes
18. Non-physician personnel performing non-bronchoscopic bronchoalveolar lavage for diagnosing ventilator associated pneumonia
19. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria
20. Methicillin-resistant Staphylococcus aureus in US hospitals, 1975-1991
21. Incidence of antibiotic resistance in blood and urine isolates from hospitalized patients: Report from a European collaborative study
22. Hospital-acquired pneumonia: Methicillin resistance and intensive care unit admission
23. Clinical and epidemiological findings in mechanically-ventilated patients with methicillin-resistant Staphylococcus aureus pneumonia
24. Longitudinal analysis of methicillin-resistant Staphylococcus aureus isolates at a teaching hospital in Taiwan
25. The independent evolution of resistance to ciprofloxacin, rifampicin, and fusidic acid in methicillin-resistant Staphylococcus aureus in Australian teaching hospitals (1990-1995)
26. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
27. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997
28. Overview of resistance in the 1990s
29. Hospital-acquired pneumonia: Epidemiology, etiology, and treatment
30. Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies: A consensus statement
31. Nosocomial pneumonia in the medical and surgical patient: Risk factors and primary management
32. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients
33. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit
34. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections
35. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents
36. Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors
37. Mechanism of action of oxazolidinones: Effect of linezolid and eperezolid on translation reactions
38. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials
39. In vitro activities of new oxazolidinone antimicrobial agents against enterococci
40. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections
41. In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species
42. In vitro activities of investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium
43. Comparative in vitro activity and postantibiotic effect of oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium
44. Comparison of linezolid versus ceftriaxone/cefpodoxime in the treatment of hospitalized patients with community-acquired pneumonia
45. Oral linezolid in the treatment of community-acquired pneumonia: A phase III trial
46. Comparison of linezolid to oxacillin followed by oral dicloxacillin in the treatment of complicated skin infections: Results from a multinational phase III trial
47. Comparison of linezolid to oral clarithromycin in the treatment of uncomplicated skin infections: Results from a multinational phase III trial
48. Linezolid in the treatment of surgical wound infections: Combined results from four phase III multinational clinical trials
49. Oxazolidinone antibacterial agents
50. Interactions of monoamine oxidase with substrates and inhibitors
51. Treatment of gram-positive nosocomial pneumonia: Prospective, randomized comparison of quinupristin/dalfopristin versus vancomycin
52. Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double-blind trial comparing intravenous ciprofioxacin with imipenem-cilastatin
53. Ceftazidime versus tobramycin-ticarcillin in the treatment of pneumonia and bacteremia
54. Prospective, randomized controlled study of ciprofloxacin versus imipenem/cilastatin in severe clinical infections
55. Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired gram-negative infections
56. Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections
57. Variations in etiology of ventilator-associated pneumonia across four treatment sites: Implications for antimicrobial prescribing practices